Drugs / Cellgram-ED
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02344849 | Jul 2015 → Jan 2018 | erectile dysfunction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04594850 | Oct 2020 → Jan 2026 | erectile dysfunction | Pharmicell Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellgram-ED | “Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days.” NCT02344849 ↗ |
| Modality | Cell therapy | “autologous Mesenchymal Stem Cells (MSC)” NCT04594850 ↗ |
| Route | Other | “single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.” NCT02344849 ↗ |